Conditions: Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 35
Healthy volunteers: no

Brief summary:
This study is intended for participants with advanced, not amenable to surgery, or metastatic lung cancer who have not received any prior chemotherapy. The study will be conducted in 2 parts:

* Part 1 is intended to evaluate safety of pemetrexed + cisplatin + enzastaurin combination chemotherapy
* Part 2 whose main objective is to compare the efficacy of pemetrexed + cisplatin + enzastaurin versus pemetrexed + cisplatin + placebo. Participants to be included in Part 2 are those with Nonsquamous Non-Small Cell Lung Cancer (NSCLC).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: enzastaurin intervention 2: pemetrexed intervention 3: cisplatin intervention 4: placebo
Intervention descriptions: intervention 1: 1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression intervention 2: 500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle intervention 3: 75 mg/m², IV, every 21 days, for each 21-day cycle intervention 4: po, QD

Protocol document: